

Natalie Eaton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2785112/publications.pdf>

Version: 2024-02-01

8
papers

138
citations

1478505

6
h-index

1720034

7
g-index

8
all docs

8
docs citations

8
times ranked

115
citing authors

#	ARTICLE	IF	CITATIONS
1	Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients. <i>Journal of Translational Medicine</i> , 2022, 20, 94.	4.4	8
2	The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP2 and NK cell function in myalgic encephalomyelitis/chronic fatigue syndrome patients. <i>Journal of Translational Medicine</i> , 2021, 19, 306.	4.4	9
3	Health-related quality of life in patients with myalgic encephalomyelitis/chronic fatigue syndrome: an Australian cross-sectional study. <i>Quality of Life Research</i> , 2020, 29, 1521-1531.	3.1	27
4	Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients. <i>Molecular Medicine</i> , 2019, 25, 14.	4.4	20
5	A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome. <i>Systematic Reviews</i> , 2019, 8, 279.	5.3	42
6	Investigation of natural killer cell function and phenotypes in stable and active multiple sclerosis patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A43.2-A43.	1.9	0
7	Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation. <i>BMC Pharmacology & Toxicology</i> , 2018, 19, 12.	2.4	3
8	Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. <i>Molecular Medicine</i> , 2018, 24, 44.	4.4	29